Greenleaf’s Drug and Biological Products Team has a robust blend of regulatory and policy expertise and FDA institutional knowledge. The team’s approach, firmly grounded in established principles of public health, is guided by decades of regulatory experience in drug and biological product development, spanning all therapeutic areas.

Greenleaf experts specialize in providing strategic and technical guidance on medical product development, regulatory review, and postmarket requirements. Greenleaf advises clients on scientific and regulatory practices for clinical programs and regulatory submissions, identification of and eligibility for special designations and expedited review programs, and preparation for FDA milestone meetings.

The team’s multidisciplinary expertise helps companies evaluating and prioritizing their drug development pipeline to understand and effectively manage regulatory risk.

Experts from the Drug and Biological Products Team also provide advisory services that include extensive research and due diligence for investors engaged in potential deals that require regulatory risk analyses before and after decisions and transactions.

Learn more about Greenleaf’s Drug & Biological Product Services:

Download Drug & Biological Products Info Sheet

Download Drug & Biological Products Capabilities Deck

Download Drug Pipeline Review Info Sheet

Greenleaf’s Drug & Biological Product Services

Unmatched Regulatory Experience

Strategic consultation on:

  • FDA regulatory programs and procedures
  • Product development
  • Endpoint and biomarker selection, development, and regulatory review
  • Premarket review
  • Postmarket safety requirements
  • Pipeline decisions and optimization

Premarket Review Process

Effective guidance on:

  • Scientific and regulatory practices for clinical programs and regulatory submissions
  • Identification of and eligibility for special designations, such as breakthrough therapy designation, RMAT, fast track, and accelerated approval
  • Preparation for FDA milestone meetings, including EOP2, pre-filing, mid-cycle review, and end-of-review meetings
  • Advisory committee meetings and decisions
  • FDA communications, including formal, in-person, and regulatory correspondence

Pipeline Review Services

Customized strategies for:

  • Effectively managing regulatory risk and reducing regulatory uncertainties
  • Planning and decision-making related to clinical programs and regulatory approval
  • Prioritizing and addressing programmatic needs for individual candidates and across the portfolio, based on systematic gap analysis
  • Drug development options, opportunities, and benchmarks

Marketing & Promotional Practices

Skilled support on:

  • Labeling requirements
  • Promotional materials
  • Direct-to-consumer advertising review processes
  • Remediation of untitled and warning letters
  • Use of social media

Regulatory Policy Guidance

Specialized insight on:

  • FDA policies and procedures
  • User fee requirements
  • Implementation of new FDA legislation, regulations, guidance documents, and FDA standard operating procedures

Drugs Team Members